Submission of Matters to a Vote of Security Holders

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (Note: Input metadata referenced "Z Squared Inc.", but the filing text identifies Coeptis Therapeutics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2024
Event: Results of the Annual Meeting of Stockholders held on December 18, 2024.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.

Material Changes and Voting Results

Approximately 65.89% of eligible voting shares were present or represented by proxy. All five proposals submitted to stockholders were approved:

  • Director Elections: Seven directors were elected (David Mehalick, Daniel Yerace, Christopher Calise, Tara Maria DeSilva, Philippe Deschamps, Christopher Cochran, and Gene Salkind). Each received over 21 million "FOR" votes.
  • Auditor Ratification: Stockholders ratified the appointment of Astra Audit & Advisory, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2023 (30,991,949 FOR vs. 1,085,521 AGAINST).
  • Reverse Stock Split: Stockholders approved an amendment to the certificate of incorporation authorizing the Board to effect a reverse stock split (29,404,035 FOR vs. 2,447,015 AGAINST).
  • Standby Equity Purchase Agreement: Stockholders approved the issuance of up to $20.0 million of securities in connection with a Standby Equity Purchase Agreement (20,764,633 FOR vs. 1,227,540 AGAINST).
  • Executive Compensation: Stockholders approved a non-binding advisory vote on the compensation of named executive officers (20,758,718 FOR vs. 1,235,121 AGAINST).

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results. The approval of the reverse stock split and the Standby Equity Purchase Agreement suggests a strategic focus on capital structure optimization and liquidity access.

Investor Verification Checklist

  • Verify the specific ratio and implementation timeline for the approved reverse stock split in subsequent filings.
  • Review the definitive terms of the Standby Equity Purchase Agreement (up to $20.0 million) to understand pricing and dilution implications.
  • Confirm the effective date of the new independent auditor, Astra Audit & Advisory, LLC.
  • Monitor the company's capital position given the approval of new equity issuance mechanisms.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.